Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis

BACKGROUND: Progression-free survival (PFS) has been adopted as the primary endpoint in many randomized controlled trials, and can be determined much earlier than overall survival (OS). We investigated whether PFS is a good surrogate endpoint for OS in trials of first-line treatment for epithelial o...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Ther Adv Med Oncol
Asıl Yazarlar: Sjoquist, Katrin M., Lord, Sarah J., Friedlander, Michael L., John Simes, Robert, Marschner, Ian C., Lee, Chee Khoon
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: SAGE Publications 2018
Konular:
Meta-Analysis
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6080081/
https://ncbi.nlm.nih.gov/pubmed/30093922
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835918788500
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller